# Empagliflozin and Hepatic Glucose Metabolism

> **NCT03193684** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 72 (actual)

## Conditions studied

- Hepatic Glucose Metabolism

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **DRUG:** Control

## Key facts

- **NCT ID:** NCT03193684
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-20
- **Primary completion:** 2023-01-30
- **Final completion:** 2024-01-30
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193684, "Empagliflozin and Hepatic Glucose Metabolism". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03193684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*